1-2 of 2
Muriel Granier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Yousif Matloub, MD, Lia Gore, MD, Mignon L. Loh, MD, Chin-Hon Pui, MD, Michael J. Hanley, PharmD, PhD, Vickie Lu, PhD, E. Jane Leonard, MSc, Muriel Granier, Andrea Biondi, MD, Lewis B. Silverman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47.
https://doi.org/10.1182/blood-2020-134724
Published: 2020
Journal Articles

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Clinical Trials & Observations
Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Huiling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood
Blood (2017) 130 (15): 1768–1771.
https://doi.org/10.1182/blood-2017-02-765032
Published: 2017
Includes: Supplemental data